Virologic failure after 48 weeks of raltegravir-based regimen in low HIV-1 incidence setting

BACKGROUND: With the advent of next generation integrase strand transfer inhibitors, the rates of virologic failure in treated subjects are expected to decrease. In this study, we analyzed the mutation patterns leading to virologic failure before and after starting integrase strand transfer inhibito...

Descripción completa

Detalles Bibliográficos
Autores principales: Chehadeh, Wassim, Albaksami, Osama, Al-Shammari, Shaikhah
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7241205/
https://www.ncbi.nlm.nih.gov/pubmed/32434393
http://dx.doi.org/10.1177/2040206620927908

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7241205/
https://www.ncbi.nlm.nih.gov/pubmed/32434393
http://dx.doi.org/10.1177/2040206620927908

Ejemplares similares